BIOAGE LABS, INC. (BIOA) Spending and interest coverage
- R&D / revenue · 12 months: Value 847.78%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 135.57%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 847.78% | Research and development expense / revenue. Period ending 2026-06-30. $87.79M ÷ $10.36M × 100 ≈ 847.78% |
| Stock-based compensation / revenue · 12 months | 135.57% | Share-based compensation / revenue. Period ending 2026-06-30. $14.04M ÷ $10.36M × 100 ≈ 135.57% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 87.79M USD | Research and Development Expense |
| Revenue | 10.36M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 14.04M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -106.27M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $87.79M | $10.36M | $14.04M | $-106.27M | (m) | 847.78% | 135.57% | (m) | (m) |
| 2026-03-31 | $83.27M | $10.32M | $13.00M | $-101.71M | (m) | 807.16% | 126.00% | (m) | (m) |
| 2025-12-31 | $73.97M | $8.99M | $11.69M | $-92.78M | (m) | 822.30% | 129.97% | (m) | (m) |
| 2025-09-30 | $68.69M | (m) | $11.69M | $-89.72M | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $70.20M | (m) | $10.75M | $-91.33M | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $60.82M | (m) | $9.08M | $-81.83M | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $59.04M | (m) | $6.98M | $-78.19M | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $33.89M | (m) | $3.02M | $-48.40M | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |